
Jiyoung Hwang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3865819/publications.pdf Version: 2024-02-01



Ινουνς Ηωλις

#	Article	IF	CITATIONS
1	Primary Colonic Epithelioid Angiosarcoma with Hepatic Metastasis: A Case Report. Journal of the Korean Society of Radiology, 2022, 83, 432.	0.2	0
2	Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. European Journal of Radiology, 2022, 151, 110328.	2.6	1
3	Utility of Diffusion-Weighted MRI for Detection of Locally Recurrent Pancreatic Cancer After Surgical Resection. American Journal of Roentgenology, 2022, 219, 762-773.	2.2	3
4	Clinical feasibility of accelerated diffusion weighted imaging of the abdomen with deep learning reconstruction: Comparison with conventional diffusion weighted imaging. European Journal of Radiology, 2022, 154, 110428.	2.6	13
5	Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. European Radiology, 2021, 31, 3315-3325.	4.5	13
6	Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor. European Journal of Radiology, 2021, 135, 109474.	2.6	5
7	Comparison of Super-Resolution US and Contrast Material–enhanced US in Detection of the Spoke Wheel Sign in Patients with Focal Nodular Hyperplasia. Radiology, 2021, 298, 82-90.	7.3	10
8	Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI. Korean Journal of Radiology, 2021, 22, 1786.	3.4	16
9	Intraductal papillary mucinous neoplasm of the pancreas: diagnostic performance of the 2017 international consensus guidelines using CT and MRI. European Radiology, 2021, 31, 4774-4784.	4.5	15
10	Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. European Radiology, 2021, 31, 7760-7770.	4.5	3
11	Modified Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging of the Prostate: Comparison With Reduced Field-of-View Imaging and Single Shot Echo-Planar Imaging. Journal of Computer Assisted Tomography, 2021, 45, 367-373.	0.9	4
12	Quantitative analysis of contrast-enhanced ultrasonography following living donor liver transplantation: early diagnosis of middle hepatic venous occlusion. Medical Ultrasonography, 2021, 23, 390-395.	0.8	0
13	EASL versus Llâ€RADS: Intraâ€individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver International, 2021, 41, 2986-2996.	3.9	11
14	Reproducibility and diagnostic performance of the vascular index of superb microvascular imaging in real-time breast ultrasonography for evaluating breast masses. Ultrasonography, 2021, 40, 398-406.	2.3	18
15	A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. European Radiology, 2021, , 1.	4.5	7
16	Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents. Korean Journal of Radiology, 2021, 22, 725.	3.4	3
17	Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Clinical Gastroenterology and Hepatology, 2020, 18, 2091-2100.e7.	4.4	34
18	Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid–enhanced MRI: A Multicenter Study. Radiology, 2020, 296, 335-345.	7.3	42

#	Article	IF	CITATIONS
19	Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. European Radiology, 2020, 30, 3723-3734.	4.5	18
20	Prognosis of resected intraductal papillary mucinous neoplasm of the pancreas: using revised 2017 international consensus guidelines. Abdominal Radiology, 2020, 45, 4290-4301.	2.1	6
21	Use of Gadoxetic Acid–enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. Radiology, 2020, 295, 114-124.	7.3	12
22	Preoperative Prediction for Early Recurrence Can Be as Accurate as Postoperative Assessment in Single Hepatocellular Carcinoma Patients. Korean Journal of Radiology, 2020, 21, 402.	3.4	22
23	Non-contrast liver MRI as an alternative to gadoxetic acid-enhanced MRI for liver metastasis from colorectal cancer. Acta Radiologica, 2019, 60, 441-450.	1.1	12
24	Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. Korean Journal of Radiology, 2019, 20, 236.	3.4	12
25	Differentiation of hypervascular primary hepatic tumors showing hepatobiliary hypointensity on gadoxetic acid-enhanced magnetic resonance imaging. Abdominal Radiology, 2019, 44, 3115-3126.	2.1	1
26	A pancreatic hemorrhagic pseudocyst with pseudoaneurysm and the role of doppler ultrasonography: a case report. Revista Da Associação Médica Brasileira, 2019, 65, 123-126.	0.7	4
27	Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI. Abdominal Radiology, 2019, 44, 2366-2376.	2.1	10
28	Differentiation between stercoral perforation and colorectal cancer perforation. Revista Da AssociaĂ§Ă£o MĂ©dica Brasileira, 2019, 65, 191-197.	0.7	6
29	Usefulness of non-contrast MR imaging in distinguishing pancreatic ductal adenocarcinoma from focal pancreatitis. Clinical Imaging, 2019, 55, 132-139.	1.5	7
30	Semiautomatic software for measurement of abdominal muscle and adipose areas using computed tomography. Medicine (United States), 2019, 98, e15867.	1.0	24
31	Usefulness of noncontrast MRI in differentiation between gallbladder carcinoma and benign conditions manifesting as focal mild wall thickening. Clinical Imaging, 2019, 54, 63-70.	1.5	13
32	Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis. Radiology, 2019, 290, 691-699.	7.3	60
33	Evaluation of early treatment response to radiotherapy for HCC using pre- and post-treatment MRI. Acta Radiologica, 2019, 60, 826-835.	1.1	7
34	Intra-individual comparison of gadolinium-enhanced MRI using pseudo-golden-angle radial acquisition with gadoxetic acid-enhanced MRI for diagnosis of HCCs using LI-RADS. European Radiology, 2019, 29, 2058-2068.	4.5	6
35	Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI. Abdominal Radiology, 2019, 44, 1395-1406.	2.1	10
36	Mesenteric Lesions with Similar or Distinctive Appearances on CT. Journal of the Korean Society of Radiology, 2019, 80, 1091.	0.2	1

#	Article	IF	CITATIONS
37	Primary Pelvic Peritoneal Yolk Sac Tumor in the Post-Pubertal Female: a Case Report with Literature Review. Investigative Magnetic Resonance Imaging, 2019, 23, 367.	0.4	0
38	Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology, 2018, 43, 2309-2320.	2.1	9
39	Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival. European Radiology, 2018, 28, 2561-2571.	4.5	7
40	Artifacts during the arterial phase of gadoxetate disodium-enhanced MRI: Multiple arterial phases using view-sharing from two different vendors versus single arterial phase imaging. European Radiology, 2018, 28, 3335-3346.	4.5	19
41	Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging. European Radiology, 2018, 28, 2549-2560.	4.5	36
42	Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. Journal of Hepatology, 2018, 68, 1144-1152.	3.7	49
43	The qualitative and quantitative image analysis of MR imaging in patients with acute-on-chronic liver failure. Clinical Imaging, 2018, 47, 18-24.	1.5	1
44	Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI. Acta Radiologica, 2018, 59, 639-648.	1.1	14
45	Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Acta Radiologica, 2018, 59, 393-401.	1.1	1
46	Comparison between MRI with MR cholangiopancreatography and endoscopic ultrasonography for differentiating malignant from benign mucinous neoplasms of the pancreas. European Radiology, 2018, 28, 179-187.	4.5	28
47	Benign versus life-threatening causes of pneumatosis intestinalis: differentiating CT features. Revista Da Associação Médica Brasileira, 2018, 64, 543-548.	0.7	11
48	Tuberculous peritonitis following intestinal perforation in malignancy. Revista Da Associação Médica Brasileira, 2018, 64, 408-412.	0.7	0
49	Breast Lesions in Children and Adolescents: Diagnosis and Management. Korean Journal of Radiology, 2018, 19, 978.	3.4	34
50	Visibility of bony structures around hip prostheses in dualâ€energy <scp>CT</scp> : With or without metal artefact reduction software. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 634-641.	1.8	4
51	Detection of recurrent hepatocellular carcinoma after surgical resection: Non-contrast liver MR imaging with diffusion-weighted imaging versus gadoxetic acid-enhanced MR imaging. British Journal of Radiology, 2018, 91, 20180177.	2.2	14
52	Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System. Hepatology, 2018, 68, 2254-2266.	7.3	87
53	Hepatic neuroendocrine tumors: gadoxetic acid-enhanced magnetic resonance imaging findings with an emphasis on differentiation between primary and secondary tumors. Abdominal Radiology, 2018, 43, 3331-3339.	2.1	11
54	Ultrasonographic features of pure ductal carcinoma in situ of the breast: correlations with pathologic features and biological markers. Ultrasonography, 2018, 37, 307-314.	2.3	11

#	Article	IF	CITATIONS
55	Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. Abdominal Radiology, 2017, 42, 1424-1433.	2.1	33
56	Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum. European Journal of Radiology, 2017, 92, 1-10.	2.6	33
57	Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI. European Radiology, 2017, 27, 4581-4590.	4.5	23
58	Diagnostic accuracy of diffusion restriction in intraductal papillary mucinous neoplasm of the pancreas in comparison with "high-risk stigmata―of the 2012 international consensus guidelines for prediction of the malignancy and invasiveness. Acta Radiologica, 2017, 58, 1157-1166.	1.1	16
59	Magnetic resonance findings of hepatic epithelioid hemangioendothelioma: emphasis on hepatobiliary phase using Gd-EOB-DTPA. Abdominal Radiology, 2017, 42, 2261-2271.	2.1	15
60	The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer. European Radiology, 2017, 27, 4383-4393.	4.5	16
61	Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants. European Radiology, 2017, 27, 3117-3127.	4.5	4
62	Reducing Artifacts during Arterial Phase of Gadoxetate Disodium–enhanced MR Imaging: Dilution Method versus Reduced Injection Rate. Radiology, 2017, 283, 429-437.	7.3	35
63	Association between non-hypervascular hypointense nodules on gadoxetic acid-enhanced MRI and liver stiffness or hepatocellular carcinoma. European Journal of Radiology, 2017, 95, 362-369.	2.6	9
64	Disappearing or residual tiny (â‰ \$ Âmm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?. European Radiology, 2017, 27, 3088-3096.	4.5	20
65	Differentiation of mass-forming focal pancreatitis from pancreatic ductal adenocarcinoma: value of characterizing dynamic enhancement patterns on contrast-enhanced MR images by adding signal intensity color mapping. European Radiology, 2017, 27, 1722-1732.	4.5	16
66	Tumefactive Gallbladder Sludge at US : Prevalence and Clinical Importance. Radiology, 2017, 283, 570-579.	7.3	18
67	Application of Three-Dimensional Volumetric Ultrasonography in Patients with Bladder Cancer and Its Mimickers: A Pictorial Essay. Journal of the Korean Society of Radiology, 2017, 76, 346.	0.2	Ο
68	Cryptogenic multifocal ulcerous stenosing enteritis: Radiologic features and clinical behavior. World Journal of Gastroenterology, 2017, 23, 4615.	3.3	27
69	Iterative reconstruction: comparison of techniques for reduced-dose liver computed tomography following transarterial chemoembolization for hepatocellular carcinoma. Acta Radiologica, 2016, 57, 1429-1437.	1.1	4
70	Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis. European Radiology, 2016, 26, 3102-3111.	4.5	30
71	Pancreatic neuroendocrine tumour: Correlation of apparent diffusion coefficient or WHO classification with recurrence-free survival. European Journal of Radiology, 2016, 85, 680-687.	2.6	21
72	T2-Weighted Liver MRI Using the MultiVane Technique at 3T: Comparison with Conventional T2-Weighted MRI. Korean Journal of Radiology, 2015, 16, 1038.	3.4	21

#	Article	IF	CITATIONS
73	Mini-Gastric Bypass to Control Morbid Obesity and Diabetes Mellitus: What Radiologists Need to Know. Korean Journal of Radiology, 2015, 16, 325.	3.4	13
74	Missed pancreatic ductal adenocarcinoma: Assessment of early imaging findings on prediagnostic magnetic resonance imaging. European Journal of Radiology, 2015, 84, 1473-1479.	2.6	24
75	Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: Impact of intra-tumoral fat detected on chemical-shift images. European Journal of Radiology, 2015, 84, 1036-1043.	2.6	43
76	Which anthropometric measurements including visceral fat, subcutaneous fat, body mass index, and waist circumference could predict the urinary stone composition most?. BMC Urology, 2015, 15, 17.	1.4	20
77	Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiologica, 2015, 56, 526-535.	1.1	39
78	Nonhypervascular Hypointense Nodules at Gadoxetic Acid–enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization. Radiology, 2015, 276, 137-146.	7.3	39
79	Acute diverticulitis of the terminal ileum: ultrasonography and CT findings. Ultrasonography, 2015, 34, 74-77.	2.3	10
80	A Case of Gastrointestinal Sarcoidosis without Pulmonary Involvement. Korean Journal of Medicine, 2015, 89, 127.	0.3	0
81	Is gadoxetic acid-enhanced MRI limited in tumor characterization for patients with chronic liver disease?. Magnetic Resonance Imaging, 2014, 32, 1214-1222.	1.8	5
82	Assessing patients with hepatocellular carcinoma meeting the milan criteria: Is liver 3 tesla MR with gadoxetic acid necessary in addition to liver CT?. Journal of Magnetic Resonance Imaging, 2014, 39, 842-852.	3.4	19
83	The Relationship Between Urinary Stone Components and Visceral Adipose Tissue Using Computed Tomography–based Fat Delineation. Urology, 2014, 84, 27-31.	1.0	12
84	Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magnetic Resonance Imaging, 2014, 32, 610-618.	1.8	59
85	The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 814-821.	0.8	23
86	Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdominal Imaging, 2013, 38, 793-801.	2.0	115
87	Scirrhous Hepatocellular Carcinoma on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging. Journal of Computer Assisted Tomography, 2013, 37, 872-881.	0.9	41
88	The MR imaging diagnosis of liver diseases using gadoxetic acid: Emphasis on hepatobiliary phase. Clinical and Molecular Hepatology, 2013, 19, 360.	8.9	22
89	Small Hepatocellular Carcinomas: Improved Sensitivity by Combining Gadoxetic Acid–enhanced and Diffusion-weighted MR Imaging Patterns. Radiology, 2012, 264, 761-770.	7.3	166
90	Hypovascular Hypointense Nodules on Hepatobiliary Phase Gadoxetic Acid–enhanced MR Images in Patients with Cirrhosis: Potential of DW Imaging in Predicting Progression to Hypervascular HCC. Radiology, 2012, 265, 104-114.	7.3	132

#	Article	IF	CITATIONS
91	Diagnostic Accuracy and Sensitivity of Diffusion-Weighted and of Gadoxetic Acid-Enhanced 3-T MR Imaging Alone or in Combination in the Detection of Small Liver Metastasis (â‰ቋ.5 cm in Diameter). Investigative Radiology, 2012, 47, 159-166.	6.2	88
92	Detection of Small Hepatocellular Carcinoma. Investigative Radiology, 2011, 46, 383-389.	6.2	35
93	Cardiovascular sources of systemic embolism: detection and characterization using multidetector CT and MR imaging. International Journal of Cardiovascular Imaging, 2011, 27, 727-744.	1.5	4
94	Differentiating focal eosinophilic liver disease from hepatic metastases using unenhanced and gadoxetic acid-enhanced MRI. Abdominal Imaging, 2011, 36, 425-432.	2.0	6
95	Computer-Aided Detection of Lung Nodules. Journal of Computer Assisted Tomography, 2010, 34, 31-34.	0.9	13
96	Gadoxetic acidâ€enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with imageâ€guided tumor therapy. Journal of Magnetic Resonance Imaging, 2010, 32, 629-638.	3.4	22
97	Papillary Thyroid Carcinoma With <i>BRAF</i> ^{V600E} Mutation: Sonographic Prediction. American Journal of Roentgenology, 2010, 194, W425-W430.	2.2	29